Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948480 · ClinicalTrials.gov registry record · Phase 2
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00948480 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 56 participants.
The verdict
NCT00948480, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.) injections of irradiated autologous tumor cells that had been established as short-term cell lines, in conjunction with their own dendritic cells (DC) and granulocyte macrophage colony-stimulating factor \[GM-CSF\]. Eligible patients had regionally recurrent and/or distant metastatic cancer.
Interventions
- DRUG GM-CSF
- BIOLOGICAL Autologous tumor cells plus dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2000-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948480
The ClinicalTrials.gov registry entry for NCT00948480 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GM-CSF is the first listed.
NCT00948480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948480 about?
NCT00948480 is a clinical study titled "Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells". This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.) injections of irradiated autologous tumor cells that had been establis...
What is the current status of trial NCT00948480?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2000-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00948480?
The interventions under investigation include: GM-CSF (DRUG), Autologous tumor cells plus dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00948480?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.